Ontology highlight
ABSTRACT: Purpose
To understand the functional and preclinical efficacy of targeting the urokinase plasminogen activator receptor (u-PAR) in ovarian cancer.Experimental design
Expression of u-PAR was studied in 162 epithelial ovarian cancers, including 77 pairs of corresponding primary and metastatic tumors. The effect of an antibody against u-PAR (ATN-658) on proliferation, adhesion, invasion, apoptosis, and migration was assessed in 3 (SKOV3ip1, HeyA8, and CaOV3) ovarian cancer cell lines. The impact of the u-PAR antibody on tumor weight, number, and survival was examined in corresponding ovarian cancer xenograft models and the mechanism by which ATN-658 blocks metastasis was explored.Results
Only 8% of all ovarian tumors were negative for u-PAR expression. Treatment of SKO
SUBMITTER: Kenny HA
PROVIDER: S-EPMC3073583 | biostudies-literature | 2011 Feb
REPOSITORIES: biostudies-literature